Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Consensus Rating of “Buy” from Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR) has been assigned an average recommendation of “Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $81.29.

Several brokerages have commented on GPCR. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, William Blair began coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating on the stock.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently made changes to their positions in GPCR. Spire Wealth Management purchased a new stake in Structure Therapeutics during the 4th quarter valued at approximately $243,000. JPMorgan Chase & Co. raised its stake in shares of Structure Therapeutics by 302.3% during the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock worth $1,489,000 after purchasing an additional 25,500 shares during the last quarter. Vestal Point Capital LP grew its position in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after buying an additional 590,000 shares during the last quarter. Barclays PLC increased its stake in Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after buying an additional 31,815 shares during the period. Finally, Pier Capital LLC raised its position in Structure Therapeutics by 32.7% during the 3rd quarter. Pier Capital LLC now owns 134,291 shares of the company’s stock worth $5,894,000 after buying an additional 33,087 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 0.4 %

Shares of GPCR opened at $21.05 on Tuesday. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -28.45 and a beta of -2.37. The firm’s fifty day simple moving average is $24.71 and its 200-day simple moving average is $31.63. Structure Therapeutics has a twelve month low of $19.39 and a twelve month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.